Literature DB >> 8467424

Epidemiology of multiple sclerosis: a critical overview.

A D Sadovnick1, G C Ebers.   

Abstract

The decisive conclusions to be drawn from the available epidemiological data, mostly geography and prevalence, of MS are: (1) a north-south (as well as west-east in the United States) gradient exists independent of genetic/racial factors; (2) major differences in prevalence occur in the absence of latitude differences; (3) individuals from the same ethnic derivation have either similar prevalence rates or very different prevalence rates in widely separated geographical areas and (4) specific resistant isolates are shown to exist regardless of latitude. Existing information leads to the almost inescapable conclusion that the epidemiology of MS cannot be explained by any single known environmental or genetic factor(s) in isolation. A combination of a heterogeneous distribution of both genetic and environmental factors appears to be required to explain the available data on MS.

Entities:  

Mesh:

Year:  1993        PMID: 8467424     DOI: 10.1017/s0317167100047351

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  43 in total

1.  Venous angioplasty in multiple sclerosis: neurological outcome at two years in a cohort of relapsing-remitting patients.

Authors:  Fabrizio Salvi; Ilaria Bartolomei; Elena Buccellato; Roberto Galeotti; Paolo Zamboni
Journal:  Funct Neurol       Date:  2012 Jan-Mar

Review 2.  Stem cell transplantation in multiple sclerosis: current status and future prospects.

Authors:  Gianvito Martino; Robin J M Franklin; Anne Baron Van Evercooren; Douglas A Kerr
Journal:  Nat Rev Neurol       Date:  2010-04-20       Impact factor: 42.937

3.  Cortical excitability changes over time in progressive multiple sclerosis.

Authors:  Samar S Ayache; Alain Créange; Wassim H Farhat; Hela G Zouari; Catherine Lesage; Ulrich Palm; Mohammed Abdellaoui; Jean-Pascal Lefaucheur
Journal:  Funct Neurol       Date:  2015 Oct-Dec

4.  Impact of natalizumab on patient-reported outcomes in a clinical practice setting: a cross-sectional survey.

Authors:  Siddhesh A Kamat; Krithika Rajagopalan; Judith J Stephenson; Sonalee Agarwal
Journal:  Patient       Date:  2009-06-01       Impact factor: 3.883

5.  Frequency of current utilisation of complementary and alternative medicine by patients with multiple sclerosis.

Authors:  Annett Apel; Brigitte Greim; Nicolaus König; Uwe K Zettl
Journal:  J Neurol       Date:  2006-06-19       Impact factor: 4.849

6.  The INTERMED: a screening instrument to identify multiple sclerosis patients in need of multidisciplinary treatment.

Authors:  E L J Hoogervorst; P de Jonge; B Jelles; F J Huyse; I Heeres; H M van der Ploeg; B M J Uitdehaag; C H Polman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-01       Impact factor: 10.154

7.  Multiple sclerosis in Jordan: A clinical and epidemiological study.

Authors:  Khalid El-Salem; Ehsan Al-Shimmery; Khalid Horany; Ali Al-Refai; Kefah Al-Hayk; Yousef Khader
Journal:  J Neurol       Date:  2006-04-28       Impact factor: 4.849

8.  A survey of endogenous retrovirus (ERV) sequences in the vicinity of multiple sclerosis (MS)-associated single nucleotide polymorphisms (SNPs).

Authors:  Christine Brütting; Alexander Emmer; Malte Kornhuber; Martin S Staege
Journal:  Mol Biol Rep       Date:  2016-05-12       Impact factor: 2.316

9.  Multiple sclerosis: myeloperoxidase immunoradiology improves detection of acute and chronic disease in experimental model.

Authors:  Benjamin Pulli; Lionel Bure; Gregory R Wojtkiewicz; Yoshiko Iwamoto; Muhammad Ali; Dan Li; Stefan Schob; Kevin Li-Chun Hsieh; Andreas H Jacobs; John W Chen
Journal:  Radiology       Date:  2014-12-10       Impact factor: 11.105

Review 10.  Pediatric multiple sclerosis.

Authors:  Brenda L Banwell
Journal:  Curr Neurol Neurosci Rep       Date:  2004-05       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.